Last Updated : March 7, 2024
Details
FilesGeneric Name:
Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus
Project Status:
Complete
Project Line:
Reimbursement Review
Project Sub Line:
Streamlined Drug Class Review
Project Number:
TS0002-000
The class of sodium-glucose cotransporter-2 (SGLT2) inhibitors is an integral part of the management of type 2 diabetes mellitus. Evidence informing the place in therapy of SGLT2 inhibitors has matured since Canada's Drug Agency last assessed this drug class. Public drug programs have requested a review to assess the optimal use of SGLT2 inhibitors after a trial of metformin.
| Posting of Draft Scope for stakeholder feedback | September 14, 2023 |
|---|---|
| End of feedback period | September 28, 2023 |
| Posting of Draft Summary Report for stakeholder feedback | October 19, 2023 |
| End of feedback period | November 2, 2023 |
| Expert committee meeting (initial) | November 30, 2023 |
| Draft recommendation(s) posted for stakeholder feedback | January 4, 2024 |
| End of feedback period | January 25, 2024 |
| Final recommendation(s) posted | March 7, 2024 |
Files
Last Updated : March 7, 2024